

# **EXHIBIT A**

**ELECTRONICALLY FILED**

Superior Court of California,  
County of Alameda

**03/07/2024 at 06:03:15 PM**

By: Damaree Franklin,  
Deputy Clerk

1 R. Brent Wisner, Esq. (SBN: 276023)  
[rbwisner@wisnerbaum.com](mailto:rbwisner@wisnerbaum.com)  
2 Stephanie Sherman, Esq. (SBN: 338390)  
[ssherman@wisnerbaum.com](mailto:ssherman@wisnerbaum.com)  
3 **WISNER BAUM, LLP**  
4 11111 Santa Monica Boulevard, Suite 1750  
Los Angeles, CA 90025  
5 Telephone: (310) 207-3233  
Facsimile: (310) 820-7444

6  
7 *Attorneys for Plaintiffs*

8 **SUPERIOR COURT OF THE STATE OF CALIFORNIA**  
9 **FOR THE COUNTY OF ALAMEDA**

10 EFREN RAMOS, JOSHUA CROSS, and  
11 MARISOL SCHARON, on behalf of themselves,  
and all others similarly situated, and the general  
12 public,

13 Plaintiffs,

14 v.

15 ALCHEMEE, LLC and DOES 1 to 50, Inclusive,

16 Defendants.  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

Case No. **24CV066886**

**CLASS ACTION COMPLAINT**

**CONSUMER FRAUD, BREACH OF  
EXPRESS & IMPLIED WARRANTIES,  
AND UNJUST ENRICHMENT**

**DEMAND FOR JURY TRIAL**

# TABLE OF CONTENTS

	Page(s)
<b>INTRODUCTION.....</b>	<b>1</b>
<b>THE PARTIES .....</b>	<b>5</b>
<b>JURISDICTION AND VENUE .....</b>	<b>6</b>
<b>GENERAL ALLEGATIONS.....</b>	<b>7</b>
I.    DESPITE DEFENDANT’S AFFIRMATIONS THAT ITS PRODUCTS ARE “BACKED BY SCIENCE,” IT DID NOT COMPLY WITH FDA’S TESTING REQUIREMENTS BEFORE SELLING THE PRODUCTS.....	8
II.   DEFENDANT KNEW OR SHOULD HAVE KNOWN THE BPO PRODUCTS DEGRADED TO BENZENE WHEN EXPOSED NORMAL USE, HANDLING AND STORAGE CONDITIONS.....	9
III.  DEFENDANT KNEW OR SHOULD HAVE KNOWN BENZENE WAS FOUND IN OTHER CONSUMER PRODUCTS BUT IT DID NOT TEST ITS BPO PRODUCTS .....	11
IV.   DEFENDANT IGNORED FDA’S BENZENE ALERT TO TEST ITS PRODUCTS .....	12
V.    RECENT TESTING FOUND COMMON BPO PRODUCTS, INCLUDING DEFENDANT’S, CONTAIN DANGEROUS LEVELS OF BENZENE IN EXCESS OF REGULATORY LIMITS.....	13
VI.   DEFENDANT EXPOSED PLAINTIFFS AND THE CLASS TO BENZENE, A KNOWN HUMAN CARCINOGEN, WITHOUT THEIR KNOWLEDGE .....	18
VII.  DEFENDANT MARKETING ITSELF AS EXPERTS BUT CONCEALED FROM PLAINTIFFS AND THE CLASS THEIR FAILURE TO TEST THE BPO PRODUCTS FOR SAFETY .....	20
VIII. DEFENDANT DID NOT WARN PLAINTIFFS AND THE CLASS THE BPO PRODUCTS WERE AT RISK OF BENZENE CONTAMINATION .....	21
IX.   DEFENDANT AGGRESSIVELY DIRECTLY MARKETING TO CHILDREN AND TEENAGERS .....	22
<b>PUNITIVE DAMAGES ALLEGATIONS.....</b>	<b>23</b>
<b>PLAINTIFF SPECIFIC ALLEGATIONS .....</b>	<b>24</b>
<b>CLASS ACTION ALLEGATIONS.....</b>	<b>26</b>
<b>CAUSES OF ACTION.....</b>	<b>29</b>

I.	VIOlation OF CALIFORNIA’S UNFAIR COMPETITION LAW BUS. & PROF. CODE § 17200 <i>et seq.</i> .....	29
II.	VIOlation OF CALIFORNIA’S CONSUMER LEGAL REMEDIES ACT, CAL. CIV. CODE § 1750, <i>et seq.</i> , .....	31
III.	VIOlation OF CALIFORNIA’S FALSE ADVERTISING LAW .....	33
IV.	BREACH OF EXPRESS WARRANTY .....	35
V.	BREACH OF IMPLIED WARRANTY .....	36
VI.	UNJUST ENRICHMENT .....	37
<b>PRAYER FOR RELIEFs .....</b>		<b>37</b>
<b>DEMAND FOR JURY TRIAL .....</b>		<b>38</b>

1 Plaintiffs, EFREN RAMOS, JOSHUA CROSS, and MARISOL SCHARON, on behalf of  
 2 themselves, the proposed California Class defined below (“the Class”), and the public, bring this Class  
 3 Action Complaint (“Class Action”) against Defendant, ALCHEMEE, LLC, alleging the following  
 4 upon Plaintiffs’ personal knowledge, or where Plaintiffs lacks personal knowledge, upon information  
 5 and belief, including the investigation of counsel.

## 6 **INTRODUCTION**

7 1. This is a consumer fraud Class Action to redress the economic harms caused by  
 8 Defendant’s sale of benzoyl peroxide acne treatment drug products (“BPO Products” or “Products”)  
 9 without warning consumers the BPO Products had unsafe levels of the potent human carcinogen  
 10 benzene, and that the BPO Products were at risk of degrading further into benzene under normal use,  
 11 handling, and storage conditions.

12 2. The BPO Products are “drugs” used to treat acne vulgaris (“acne”), formulated with a  
 13 chemical called benzoyl peroxide (“BPO”), along with other inactive ingredients, to make acne  
 14 treatment creams, washes, scrubs, and bars. Before being sold to the public, the Products must be  
 15 made in conformity with current good manufacturing practices and must conform to quality, safety,  
 16 and purity specifications. Defendant’s BPO Products did not.

17 3. BPO Products should not have benzene, nor degrade into benzene, except under  
 18 extraordinary circumstances.<sup>1</sup> A drug is “adulterated” if it consists in whole or in part of any filthy,  
 19 putrid, or decomposed substance, is impure, or mixed with another substance.<sup>2</sup> Under the Federal  
 20 Food, Drug and Cosmetic Act, it is a crime to introduce or deliver “into interstate commerce any food,  
 21 drug, device, tobacco product, or cosmetic that is adulterated or misbranded.”<sup>3</sup> If benzene is found in  
 22 any on-market or post-market Product, the drug is adulterated, unlawful and the drug manufacturer  
 23 must contact the Food and Drug Administration (“FDA”) initiate a voluntary recall.<sup>4</sup>

24 4. Throughout this Complaint, references to federal law and FDA regulation are merely to

25 <sup>1</sup> Food and Drug Administration, *Q3C – Tables and List Guidance for Industry* (2017),  
 26 <https://www.fda.gov/media/71737/download>.

27 <sup>2</sup> 21 U.S.C. § 351(a)(2011); *see also* § 351(b)-(d) (noting that a lack of purity or mixture with another substance  
 also renders drug adulterated).

28 <sup>3</sup> 21 U.S.C. § 331(a)(2011).

<sup>4</sup> Food and Drug Administration. (Dec. 22, 2022). *FDA Alerts Drug Manufacturers to the Risk of Benzene in Certain Drugs*, <https://www.fda.gov/drugs/pharmaceutical-quality-resources/fda-alerts-drug-manufacturers-risk-benzene-contamination-certain-drugs> (last visited Feb. 9, 2024).

1 provide context and are not intended to raise a federal question of law. All claims alleged herein arise  
 2 out of violations of state law, which in no way conflict, interfere with, or impose obligations that are  
 3 materially different than those imposed by federal law.

4 5. The BPO Products marketed and sold by Defendant to Plaintiffs, the California Class,  
 5 and the public decomposed into benzene rendering them materially different than advertised, *i.e.*, by  
 6 containing unsafe levels of benzene. Benzene is a known human carcinogen. Studies dating to the  
 7 1800s have led to a consensus within the medical and scientific communities that benzene exposure,  
 8 even in low amounts, increases the risk of blood cancers and other adverse effects.

9 6. In 2023, Valisure, LLC,<sup>5</sup> an independent, accredited laboratory that has developed  
 10 analytical methods to test drugs and consumer products for public safety, tested a representative  
 11 sample of BPO and non-BPO products and found the BPO Products had dangerous levels of benzene,  
 12 many multiple times higher than allowed in any regulated drug.<sup>6</sup> Using industry standard gas  
 13 chromatography and detection by mass spectrometry (“GC-MS”) instrumentation, with selected ion  
 14 flow tube mass spectrometry (“SIFT-MS”) for detection of benzene released into the air around  
 15 certain BPO Products, the Products were incubated to temperatures common during consumer use,  
 16 handling, and storage and sampled for benzene.<sup>7</sup> Levels as high as 1600 parts per million (ppm) were  
 17 found in Defendant’s Product, 2.5% Cream.<sup>8</sup> Unexpectedly, researchers found that benzene was  
 18 released into the surrounding air outside the Products’ containers even when the packaging and  
 19 containers were closed raising concern for even more inhalation exposures—a particularly pernicious  
 20

---

21 <sup>5</sup> Valisure is an independent third-party analytical laboratory that is accredited to International Organization for  
 22 Standardization (“ISO/IEC”) 17025:2017 standards for chemical testing (PJLA Accreditation Number 94238). In  
 23 response to rising concerns about drug shortages, generics, and overseas manufacturing, Valisure developed and validated  
 24 methods to test medications and consumer products distributed in the United States. Valisure has tested a variety of drug  
 25 and consumer healthcare products for benzene including sunscreens, antiperspirants, body sprays, hand sanitizers, and dry  
 26 shampoos for benzene. Valisure’s testing results submitted to the FDA in its Citizen’s Petitions, were widely publicized in  
 27 the media leading to numerous recalls of contaminated consumer products. *See* Valisure Citizen’s Petition on Benzoyl  
 Peroxide (March 4, 2024), pp. 6-7, *see also* Valisure Detects Benzene in Sunscreen, <https://www.valisure.com/valisure-newsroom/valisure-detects-benzene-in-sunscreen>; Bruce Y. Lee, Forbes, FDA: P&G Recalls Antiperspirant Sprays Due To Cancer Risk Of Benzene (Nov. 24, 2021), <https://www.forbes.com/sites/brucelee/2021/11/24/fda-pg-recalls-antiperspirants-body-sprays-due-to-cancer-risk-of-benzene/?sh=69cf13c24f32>; *see also* Sandee LaMotte, CNN, Antiperspirant recall: What the finding of a cancer-causing chemical means for you (Dec. 1, 2021), <https://www.cnn.com/2021/12/01/health/deodorants-antiperspirants-recall-benzene-explainer-wellness/index.html>.

28 <sup>6</sup> Valisure FDA Citizen’s Petition on Benzoyl Peroxide (March 6, 2024).

<sup>7</sup> *Id.*

<sup>8</sup> *Id.* at 17.

1 form of exposure to benzene.<sup>9</sup> For the non-BPO products tested, benzene was not present, or at trace  
 2 levels below 2 ppm.<sup>10</sup> Valisure filed a FDA Citizen's Petition on March 5, 2024 demanding an  
 3 immediate recall of all BPO Products.<sup>11</sup> The Petition is pending.<sup>12</sup>

4 7. The high levels of benzene found led Valisure to conduct a stability study on a diverse  
 5 market sweep of BPO Products and formulations. Valisure's results show that on-market BPO  
 6 Products can form over 800 times the conditionally restricted FDA concentration limit of 2 ppm for  
 7 benzene, and the evidence suggests this problem applies broadly to BPO Products currently on the  
 8 market.<sup>13</sup> Valisure concluded that on-market BPO Products appear to be fundamentally unstable and  
 9 form unacceptably high levels of benzene when handled or stored at temperatures the Products will be  
 10 exposed to during expected use and handling by consumers.<sup>14</sup>

11 8. Although the BPO Products have been found to have benzene, Defendant never listed  
 12 benzene among the its Products' ingredients, or anywhere on the Products' labels, containers,  
 13 advertising or on Defendant's websites. Defendant never warned anyone the Products had benzene or  
 14 were at risk of benzene contamination.

15 9. Defendant knew or should have known its BPO Products contain and/or degraded into  
 16 benzene when exposed to expected consumer use, handling, and storage conditions. BPO is known,  
 17 within the scientific community (but not among consumers) to degrade into benzene according to the  
 18 mechanism below:<sup>15</sup>

---

19 <sup>9</sup> *Id.* at 23.

20 <sup>10</sup> *Id.* at 15 ("76 non-BPO products had no detectable benzene or values below 0.1ppm. 6 non-BPO products  
 21 contained traces of benzene below 2 ppm, which could be due to various inactive ingredients used in consumer products  
 22 that have been theorized to contain trace benzene"); *see also* Valisure, LLC, [https://www.valisure.com/valisure-](https://www.valisure.com/valisure-newsroom/valisure-detects-benzene-in-benzoyl-peroxide)  
[newsroom/valisure-detects-benzene-in-benzoyl-peroxide](https://www.valisure.com/valisure-newsroom/valisure-detects-benzene-in-benzoyl-peroxide) (last visited March 6, 2024).


23 <sup>11</sup> Valisure's Citizen Petition on Benzene in Benzoyl Peroxide Products (March 5, 2024), *available at*:  
<https://www.valisure.com/valisure-newsroom/valisure-detects-benzene-in-benzoyl-peroxide> (last visited March 7, 2024).

24 <sup>12</sup> Valisure's Citizen's Petition was still pending as of this Class Action's filing.

25 <sup>13</sup> Valisure, LLC, (March 6, 2024), *Valisure Discovers Benzoyl Acne Treatment Products are Unstable and Form*  
*Benzene*, <https://www.valisure.com/valisure-newsroom/valisure-detects-benzene-in-benzoyl-peroxide> (last visited March  
 26 6, 2024).

27 <sup>14</sup> *Id.*

28 <sup>15</sup> The disposition of benzoyl peroxide to form benzene. Benzoyl peroxide is known to thermally decompose to  
 form two molecules of benzoyloxy radicals that can further decompose to benzoic acid or phenyl radicals with liberation of  
 carbon dioxide. The phenyl radicals can then produce benzene. *See* Shang-Hao Liu, et al, *Thermal hazard evaluation of*  
*the autocatalytic reaction of benzoyl peroxide using DSC and TAM III*, THERMOCHIMICA ACTA, Volume 605, Pages 68-76, ,  
 (2015), ISSN 0040-603, <https://www.sciencedirect.com/science/article/pii/S004060311500057X>.



10. Defendant misled the Plaintiffs, the California Class, and the public by representing its BPO Products only had the ingredients listed on the labels, packaging, containers, and on its website. Defendant misled the Plaintiffs, the California Class, and the public by representing the BPO Products were safe while concealing material health and safety information known to them, *e.g.*, that the BPO Products degraded to benzene, or were contaminated with benzene. Defendant misled Plaintiff, the California Class, and the public by giving the BPO Products long expiration dates of 2-3 years, leading consumers to believe the Products were safe for use for years when Defendant knew or should have known the Products degraded into benzene much sooner and were likely already contaminated by the time the Products were first used by the consumer.

11. Defendant's statements and omissions of material health and safety information are prohibited deceptive trade practices and false and deceptive advertising. Defendant's statements about the Products were false, misleading, unsubstantiated, untruthful, and blatantly deceptive. Even more egregious is Defendant unreasonably placed Plaintiffs, the California Class, and the public at risk of exposure to benzene, and at increased risk of cancer, without their knowledge and consent.

12. Because of the Defendant's misconduct and consumer deception, the Plaintiffs and the California class were economically harmed, as they bought Products they otherwise would have never bought. They were also physically harmed by being exposed to a known human carcinogen.

13. This Class Action is necessary to redress the economic harms caused to the Plaintiffs and the California Class members who bought the Products believing them to be safe. This Class



1 Action is further necessary to expose Defendant's ongoing consumer fraud and to enjoin Defendant  
2 from continuing their misconduct to protect consumers and the public.

3 14. Plaintiffs bring this Class Action individually, and on behalf of those similarly situated,  
4 and seek to represent a California Class of consumers who bought the Products. Plaintiffs seek  
5 damages, reasonable attorneys' fees and costs, interest, restitution, and all other equitable relief,  
6 including an injunction and disgorgement of all benefits and profits Defendant received from their  
7 misconduct.

### 8 **THE PARTIES**

9 15. Plaintiff Efren Ramos is a California resident, located in Alameda County, who bought  
10 Defendant's BPO Products including, but not limited to, Proactiv Renewing Cleanser from 2017 to  
11 February 2024. Plaintiff has suffered economic damages and as a result of Defendant's violations of  
12 the state laws alleged. Plaintiff would never have bought the Product had Defendant warned about the  
13 presence of benzene or that the Product could degrade into benzene.

14 16. Plaintiff Joshua Cross is a California resident, located in San Francisco County, who  
15 bought Defendant's BPO Products including, but not limited to, Proactiv+ Skin Smoothing Exfoliator,  
16 Proactiv Solution® Repairing Treatment, Proactiv Solution® Renewing Cleanser, Proactiv+ Pore  
17 Targeting Treatment, and Proactiv Emergency Blemish Relief from January 2002 to December 2023.  
18 Plaintiff has suffered economic damages and a result of Defendant's violations of the state laws  
19 alleged. Plaintiff would never have bought Defendant's BPO Products had Defendant warned about  
20 the presence of benzene or that the Products could degrade into benzene.

21 17. Plaintiff Marisol Scharon is a California resident, located in Los Angeles County, who  
22 bought Defendant's BPO Products including, but not limited to, Proactiv Solution® Repairing  
23 Treatment, Proactiv Solution® Renewing Cleanser, Proactiv+ Pore Targeting Treatment, and Proactiv  
24 Emergency Blemish Relief from August 2016 to March 2021. Plaintiff has suffered economic  
25 damages and a result of Defendant's violations of the state laws alleged. Plaintiff would never have  
26 bought Defendant's BPO Products had Defendant's warned about the presence of benzene or that the  
27 Products could degrade into benzene.

28 18. Defendant Alchemee LLC ("Alchemee") is a citizen of California with its principal

place of business at 120 Broadway, Suite 500, Santa Monica, California 90401. Defendant sells and distributes BPO Products under the brand name Proactiv. The Proactiv Products include, *inter alia*: (1) Proactiv+ Skin Smoothing Exfoliator, (2) Proactiv Solution® Repairing Treatment, (3) Proactiv Solution® Renewing Cleanser, (4) Proactiv+ Pore Targeting Treatment, and (5) Proactiv Emergency Blemish Relief. At all relevant times, Defendant conducted business and derived substantial revenue from its manufacturing, advertising, marketing, distributing, and selling of the BPO Products within the State of California and within Alameda County, California.

19. Defendant and its agents promoted, marketed, and sold the BPO Products within California and in Alameda County, California. The unfair, unlawful, deceptive, and misleading advertising and labeling of the BPO Products were prepared and/or approved by Defendant and its agents and were disseminated by Defendant and its agents through labeling and advertising containing the misrepresentations alleged that were disseminated uniformly to Plaintiffs and the Class through advertising, packaging, containers, and through Defendant's websites and social media.

#### **JURISDICTION AND VENUE**

20. This Court has jurisdiction over this action pursuant to the California Constitution Article VI, Section 10, which grants the Superior Court "original jurisdiction in all causes except those given by statute to other trial courts." The Statutes under which this action is brought do not specify any other basis for jurisdiction.

21. This Complaint does not involve any non-California class members or any non-Californian Defendants.

22. Venue is proper in Alameda County, California pursuant to CCP § 395(a) because it is the county where Plaintiff Ramos's injury to personal property occurred.

23. This Court has general personal jurisdiction over Defendant because Defendant is a citizen of California and headquartered in California. Additionally, Defendant is authorized and licensed to conduct business in California, maintains and carries on systematic and continuous contacts in California, regularly transacts business within the State of California, and regularly avails itself of the benefits of the State of California, including Alameda County, where it sells Products and engaged in misconduct that has and had a direct, substantial, reasonably foreseeable, and the intended

1 effect of injuring people in the State of California, and within Alameda County, California.

2 Additionally, the claims by Plaintiffs arise out of and relate to the Defendant's action within the State  
3 of California and in Alameda County.

#### 4 **GENERAL ALLEGATIONS**

5 24. Fifty million Americans suffer from acne yearly.<sup>16</sup> Acne is the most common skin  
6 condition in the U.S. with a prevalence among adolescents of almost 95 percent.<sup>17</sup> Acne can begin as  
7 early as age seven and, for some, can persist through adulthood and into ages 50s and 60s.<sup>18</sup> Millions  
8 of acne sufferers seek treatment every year making it a billion-dollar industry.

9 25. Proactiv is the brand name for Defendant's BPO Products, which are distributed in the  
10 U.S. by Defendant from its headquarters in Santa Monica, California. To make Defendant's BPO  
11 Products, BPO, a dry white powder, is mixed with other inactive ingredients to create topical drug  
12 creams, cleansers, scrubs, and washes for use on the face and body. BPO is formulated into these  
13 Products at concentrations up to 10%. Defendant's BPO Products include: Proactiv+ Skin Smoothing  
14 Exfoliator, Proactiv Solution® Repairing Treatment, Proactiv Solution® Renewing Cleanser,  
15 Proactiv+ Pore Targeting Treatment, and Proactiv Emergency Blemish Relief. None of these  
16 Products list benzene anywhere as an ingredient or contaminant.

17 26. Proactiv is Defendant's "powerhouse" acne treatment brand. The Proactive BPO  
18 Products are widely marketed, available, sold, and used by children, teenagers, and adults throughout  
19 the U.S. and are abrasively marketed on social media sites like Tik Tok (and its predecessor),  
20 Instagram, and Snap Chat, which skew towards younger viewers. Defendant consistently advertised  
21 Proactiv as "America's #1 acne routine."

22 27. The acne treatment industry is a highly competitive, billion-dollar market. To gain  
23 consumer trust and interest, Defendant told the Plaintiffs, the Class, and consumers "we're on a  
24 mission to become the leading global science-backed, regimen-based skincare company guided by the  
25  
26  
27

28 <sup>16</sup> American Association of Dermatology, <https://www.aad.org/media> (visited October 24, 2023).

<sup>17</sup> JL Burton et al., *The prevalence of acne vulgaris in adolescence*, BR J DERMATOL, (1971);85(2):119–126.

<sup>18</sup> *Id.*

needs of our customers as well as the latest research, products and trends.”<sup>19</sup> Defendant said it had a “history of leveraging science to create effective and powerful wellness solutions.”<sup>20</sup> Defendant told Plaintiffs and the Class in 2021 it will continue to “lean into our long-standing partnerships with leading experts in the field while pushing forward to develop science-backed innovation.”<sup>21</sup> Defendant made these statements and promises to influence the Plaintiffs and Class members purchasing decisions so they would buy Defendant’s Products.

28. Defendant consistently marketed itself and Proactiv as science based. Defendant has a “scientific advisory board,” that includes board certified dermatologists.<sup>22</sup> Defendant’s parent company, Taro told consumers it employs hundreds of scientists globally with 16% of its employees working in research and development.<sup>23</sup>

**I. DESPITE DEFENDANT’S AFFIRMATIONS THAT ITS PRODUCTS ARE “BACKED BY SCIENCE,” IT DID NOT COMPLY WITH FDA’S TESTING REQUIREMENTS BEFORE SELLING THE PRODUCTS**

29. Defendant said it employed scientists, researchers, a scientific advisory board, board certified physicians, and engaged with leading experts to create “science based” Products, yet it did not adequately test the Products for safety before selling them. Defendant’s Products are “drugs” regulated by the FDA. As with any regulated drug, Defendant must follow current good manufacturing practices (“CGMPs”), have scientifically sound specifications, and must have test procedures and processes to ensure the drug’s components (active and inactive ingredients), and finished products are safe. Both raw ingredient materials and finished batches must be tested before released to the public to confirm they meet specifications for identity, strength, quality, and purity.<sup>24</sup> If testing results of the raw materials or finished product do not conform with the specifications, the product cannot be sold to the public. Defendant must also re-test any Products subject to

<sup>19</sup> PR Newswire (Nov. 30, 2021), *The Proactiv Company Announces Transition to Alchemee and Expansion of Regimen Based Skin Care Offerings*, retrieved from: <https://www.prnewswire.com/news-releases/the-proactiv-company-announces-transition-to-alchemee-and-expansion-of-regimen-based-skincare-offerings-301433893.html> (last visited March 7, 2024).

<sup>20</sup> *Id.*

<sup>21</sup> *Id.*

<sup>22</sup> See Proactiv.com, *Face Forward, Science Backed*, retrieved from: <https://www.proactiv.com/> (last visited March 7, 2024).

<sup>23</sup> Taro Pharmaceuticals Industries, Ltd., USA (March 31, 2023) *Form 20-F*, <http://www.sec.gov/edgar.shtm>.

<sup>24</sup> 21 C.F.R. § 211.84 (1978); *see also* 21 C.F.R. § 211.160 (1978).

deterioration.<sup>25</sup> Any Products not made in conformity with the CMGPs is considered “adulterated” under 501(a)(2)(B) of the Food, Drug, and Cosmetic Act.<sup>26</sup> It is illegal to introduce “adulterated” drugs into the U.S. market.<sup>27</sup>

30. Defendant must also do stability testing to understand the “shelf life” of the Products and to assign an expiration date. It is well known that certain chemical ingredients can degrade or change because of environmental, and storage conditions such as light, moisture, temperature, and humidity, or because of the passage of time. The stability testing should cover all expected distributor and consumer storage, handling, and use conditions and must be done using “reliable, meaningful, and specific test methods.”<sup>28</sup> If any stability testing finds that a BPO Product is not stable under expected storage or use conditions, degrades, or create toxic byproducts, the Product cannot be sold to the public.

31. The CGMPs and stability test requirements are there to ensure drug products are safe for public use. These are the minimum requirements. Because the drug manufacturers are largely self-regulated, the FDA must rely on drug manufacturers, the public, and concerned citizens to report unsafe drugs. The FDA cannot force a drug manufacturer to recall a contaminated drug.<sup>29</sup>

## **II. DEFENDANT KNEW OR SHOULD HAVE KNOWN THE BPO PRODUCTS DEGRADED TO BENZENE WHEN EXPOSED NORMAL USE, HANDLING AND STORAGE CONDITIONS**

32. Defendant knew or should have known the BPO Products degraded to benzene when exposed to heat. Defendant knew that, because of the chemical nature of the active and inactive ingredients, including BPO, the BPO Products were not stable and would degrade when exposed to heat from normal distributor and consumer use, handling, and storage conditions.

33. It is well known that BPO degrades to benzene when exposed to heat over time. This

<sup>25</sup> 21 C.F.R. § 211.160(b)(1)(1978).


<sup>26</sup> 21 C.F.R. § 225.1 (1976). Under 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act a drug is considered “adulterated” (poorer in quality by adding another substance) if the methods used in, or the facilities or controls used for, its manufacture, processing, packing, or holding do not conform to or are not operated or administered in conformity with CGMP; *see also* Food and Drug Administration, *Facts About the Current Good Manufacturing Practices (CGMP)*; <https://www.fda.gov/drugs/pharmaceutical-quality-resources/facts-about-current-good-manufacturing-practices-cgmp> (last visited Feb. 11, 2024).

<sup>27</sup> See Food, Drug, and Cosmetic Act, 21 U.S.C. § 331(a)(2011).

<sup>28</sup> 21 CFR 211.166.

<sup>29</sup> Food and Drug Administration, *Facts About the Current Good Manufacturing Practices (CGMP)*; <https://www.fda.gov/drugs/pharmaceutical-quality-resources/facts-about-current-good-manufacturing-practices-cgmp> (last visited Feb. 11, 2024).

process was first reported in the scientific literature as early as 1936.<sup>30</sup> BPO degrades into benzene according to the mechanism below.<sup>31</sup>



34. The degradation of BPO to benzene was known or should have been known to the Defendant, who consistently marketed itself to Plaintiffs and the Class as dedicated to science, safety, and research, and who said to employed scientists, and leading experts.

35. Defendant further knew or should have known that specific ingredients derived from hydrocarbons increased the risk the BPO Products would yield benzene.<sup>32</sup> At-risk ingredients include carbomers, mineral spirits, and other petroleum derived substances. These ingredients are red flags for risk of benzene contamination. The FDA published guidance in 2022 urging the industry to reformulate drug products at risk of benzene contamination.<sup>33</sup> The FDA's alert highlighted ingredients made from hydrocarbons, including carbomers (thickening agents), urging drug manufacturers to test products containing them for benzene contamination.<sup>34</sup>

36. Defendant knew or should have known through their own research, development, formulation, manufacturing, and testing whether its BPO Products were chemically and physically stable. Defendant was required not only to adequately test its BPO Products for safety and stability

<sup>30</sup> H. Erlenmeyer and W. Schoenauer, *Über die thermische Zersetzung von Di-acyl-peroxyden*, HELV. CHIM. ACTA, 19, 338 (1936), <https://onlinelibrary.wiley.com/doi/10.1002/hlca.19360190153> (last visited Feb. 5, 2024).

<sup>31</sup> Benzoyl peroxide is known to thermally decompose to form two molecules of benzoyloxy radicals that can further decompose to benzoic acid or phenyl radicals with liberation of carbon dioxide. The phenyl radicals can then produce benzene. See Shang-Hao Liu et al., *Thermal hazard evaluation of the autocatalytic reaction of benzoyl peroxide using DSC and TAM III*, THERMOCHIMICA ACTA, Volume 605, (2015), Pages 68-76, ISSN 0040-6031, <https://www.sciencedirect.com/science/article/pii/S004060311500057X> (last visited Feb. 5, 2024).

<sup>32</sup> Food and Drug Administration. (Dec. 22, 2022). *FDA Alerts Drug Manufacturers to the Risk of Benzene in Certain Drugs*.

<sup>33</sup> Food and Drug Administration. *Reformulating Drug Products That Contain Carbomers Manufactured With Benzene* (December 27, 2023), <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/reformulating-drug-products-contain-carbomers-manufactured-benzene>.

<sup>34</sup> *Id.*; see also December 22, 2022 FDA Alert at 1.

1 before selling them, but also to monitor their internal practices, processes, and specifications to make  
2 sure they kept pace with science and emerging methodologies. Publicly at least, Defendant said it was  
3 doing so. Defendant said in 2021 it was “on a mission to be the leading global science-backed,  
4 regimen-based skincare company.”<sup>35</sup>

5 37. Defendant knew or should have known the BPO Products would be handled, used, and  
6 stored by distributors, sellers, and consumers under various temperatures that affect chemical stability.  
7 Defendant knew or should have known the BPO Products would travel by commercial carriers and  
8 distributors in varying storage conditions and would be stored by consumers in handbags, backpacks,  
9 bathrooms, showers, lockers, and in vehicles during warm months where the BPO Products would be  
10 exposed to heat. Defendant knew or should have known consumers would apply the benzene  
11 contaminated BPO Products to their faces and bodies and would also use the BPO Products in heated  
12 showers as scrubs and washes. Defendant knew or should have known the BPO Products would be  
13 used and applied to the skin at normal body temperatures, and elevated temperatures following  
14 showers or baths, after physical activity, and after the BPO Products sat in warm temperatures or hot  
15 vehicles.

16 38. These storage, use, and handling conditions were known or should have been known to  
17 Defendant before the BPO Products were sold to Plaintiffs and the Class. Defendant knew or should  
18 have known the BPO Products degraded to benzene under these conditions exposing consumers to  
19 benzene. Defendant further knew or should have known that, because of the known degradation of  
20 BPO to benzene, their BPO Products were contaminated with benzene by the time they reached  
21 consumers, but they sold them to Plaintiffs and the Class anyway, without warning of the risk of  
22 exposure to benzene.

23 **III. DEFENDANT KNEW OR SHOULD HAVE KNOWN BENZENE WAS FOUND IN**  
24 **OTHER CONSUMER PRODUCTS BUT IT DID NOT TEST ITS BPO PRODUCTS**

25 39. Defendant knew or should have known benzene contamination was found in other on-

---

26  
27 <sup>35</sup> See PR Newswire (Nov. 30, 2021), *The Proactiv Company Announces Transition to Alchemee and Expansion*  
28 *of Regimen Based Skin Care Offerings*, retrieved from: <https://www.prnewswire.com/news-releases/the-proactiv-company-announces-transition-to-alchemee-and-expansion-of-regimen-based-skincare-offerings-301433893.html> (last visited March 7, 2024).



market drug and healthcare products but did not test its BPO Products for benzene. In 2020, the FDA started working with companies to identify benzene in products, which resulted in product recalls of hand sanitizers, sunscreens, and deodorants. In 2021, an independent chemical analysis by Valisure of hundreds of sunscreens and after-sun care products from 69 brands found 27 percent of the batches had significant levels of benzene above the FDA 2 ppm limit.<sup>36</sup> Johnson and Johnson's Aveeno and Neutrogena sunscreen lines were among the most benzene contaminated and were recalled.<sup>37</sup> CVS's private brand after-sun care products were also highly contaminated with benzene, but not recalled by CVS. The contamination of these consumer products was widely reported around the world. By 2021, Defendant was aware of the benzene contamination issues in many drug and consumer products but continued to sell its BPO Products without testing them for benzene.

#### **IV. DEFENDANT IGNORED FDA'S BENZENE ALERT TO TEST ITS PRODUCTS**

40. In 2022, the FDA issued a safety alert warning drug manufacturers of the risk of benzene contamination in certain drug products and drug components. The FDA reiterated the risk benzene exposure poses to public health and the drug manufacturers' obligations to test drug products under the U.S. Code of Federal Regulations, Title 21:

FDA reminds manufacturers they are required to establish scientifically sound and appropriate specifications and test procedures to assure drug components (active and inactive ingredients) and finished drug products conform to appropriate quality specifications (21 C.F.R. 211.84, 21 C.F.R. 211.160). This includes testing of raw materials and finished batches (21 C.F.R. 211.165) prior to release to ensure they meet appropriate specifications for identity, strength, quality, and purity.<sup>38</sup>

41. The FDA warned drug manufacturers that any drug products or components at risk of benzene contamination should be tested, and any batches with benzene above 2 ppm should not be released to the public.<sup>39</sup> The FDA warned that, if any drug or drug component was subject to deterioration, drug manufacturers must have re-testing procedures in place to ensure continued purity and stability. The FDA recommended risk assessments to evaluate the possibility of benzene

<sup>36</sup> Valisure Citizen Petition on Benzene in Sunscreen and After-sun Care Products, May 24, 2021.

<sup>37</sup> Press Release. (July 14, 2021), Johnson & Johnson Consumer Inc. *Johnson & Johnson Consumer Inc. Voluntarily Rec of Specific Neutrogena and Aveeno Aerosol Sunscreen Products Due to the Presence of Benzene.*

<sup>38</sup> Federal Drug Administration. (Dec. 22, 2022). *FDA Alerts Drug Manufacturers to the Risk of Benzene in Certain Drugs*, 1.

<sup>39</sup> *Id.*, 3.



contamination in the drug products or components.<sup>40</sup> If any drug product in circulation was found to have benzene over 2ppm, the FDA directed that drug manufacturers contact the FDA to discuss a voluntarily recall.<sup>41</sup>

42. To date, none of the Defendant's BPO Products have been recalled due to benzene contamination, and Defendant has released no data showing its BPO Products are not contaminated with benzene.

## **V. RECENT TESTING FOUND COMMON BPO PRODUCTS, INCLUDING DEFENDANT'S, CONTAIN DANGEROUS LEVELS OF BENZENE IN EXCESS OF REGULATORY LIMITS**

43. Testing by Valisure in 2023 found common acne treatment products formulated with BPO are not only contaminated with benzene but have levels dangerous to public health. Valisure is an accredited independent laboratory who has developed validated analytical methods<sup>42</sup> to test drugs and consumer products to address rising concerns about public safety. Valisure has tested a wide variety of drugs and products for benzene including sunscreens, antiperspirants, hand sanitizers, and dry shampoos. Their work has led to widely publicized product recalls protecting the public from dangerous and carcinogenic consumer products.<sup>43</sup>

44. In 2023, Valisure tested 175 finished acne treatment products to determine whether any had benzene. Of the 175 products tested, 99 were formulated with BPO, 58 had active ingredients

---

<sup>40</sup> *Id.*


<sup>41</sup> *Id.*, 2.

<sup>42</sup> Valisure's test methods largely mirror those utilized by FDA's own "Drug Quality Sampling and Testing" ("DQST") Program. Valisure FDA Citizen's Petition at 4.

<sup>43</sup> See Valisure May 24, 2021 Citizen Petition on Benzene in Sunscreen and After-sun Care Products, <https://www.valisure.com/valisure-newsroom/valisure-detects-benzene-in-sunscreen>; Valisure's Citizen Petition on Hand Sanitizer Products Containing Benzene Contamination (filed March 24, 2021), <https://www.regulations.gov/document/FDA-2021-P-0338-0001>, Valisure's Citizen Petition on Benzene in Sunscreen and After-sun Care Products (filed May 24, 2021), <https://www.regulations.gov/document/FDA-2021-P-0497-0001>, Valisure's Citizen Petition on Benzene in Body Spray Products (filed November 3, 2021), <https://www.regulations.gov/document/FDA-2021-P-1193-0001>, Valisure's Citizen Petition on Benzene in Dry Shampoo Products (filed October 31, 2022), <https://www.regulations.gov/document/FDA-2022-P-2707-0001> see also CNET, Dry Shampoo Recall: What Is Benzene and Which Brands Are Affected <https://www.cnet.com/health/personal-care/dry-shampoo-recall-what-is-benzene-and-which-brands-are-affected/> (identifying 19 types of dry shampoo have been recalled due to benzene content); Ryan Basen, Medpage Today, After Valisure Petition, Ol' Dirty Benzene Forces Another Recall (November 30, 2021), <https://www.medpagetoday.com/special-reports/exclusives/95929> ("After Valisure Petition, Ol' Dirty Benzene Forces Another Recall"); Bruce Y. Lee, Forbes, FDA: P&G Recalls Antiperspirant Sprays Due To Cancer Risk Of Benzene (Nov. 24, 2021), <https://www.forbes.com/sites/brucelee/2021/11/24/fda-pg-recalls-antiperspirants-body-sprays-due-to-cancer-risk-of-benzene/?sh=69cf13c24f32>; see also Sandee LaMotte, CNN, Antiperspirant recall: What the finding of a cancer-causing chemical means for you (Dec. 1, 2021), <https://www.cnn.com/2021/12/01/health/deodorants-antiperspirants-recall-benzene-explainer-wellness/index.html>.

(either individually or in combination) of salicylic acid, sulfur, adapalene, azelaic acid, niacinamide and zinc, and 18 had no drug ingredients.<sup>44</sup> 83 of the BPO Products were purchased over the counter from major retailers and 16 were prescription products purchased from licensed wholesalers.<sup>45</sup> The BPO Products included popular Products: Proactiv 2.5% BPO Cream, Target Up & Up 2.5% BPO Cream, Equate Beauty 10% BPO Cream, Equate BPO Cleanser, Neutrogena 10% BPO Cleanser, Clearasil 10% BPO Cream, CVS Health 10% BPO Face Wash, Walgreens 10% BPO Cream, La Roche Posay BPO Cream, and Clean & Clear 10% BPO Lotion.

45. Valisure used three incubation temperatures to evaluate the effects of common distributor and consumer use, handling, and storage conditions on benzene formation. 37°C/98.6°F was used for human body temperature, 50°C/122°F was used to evaluate shelf-life performance as an accelerated stability testing temperature used by the pharmaceutical industry,<sup>46</sup> and 70°C/158°F to model storage in a hot vehicle.<sup>47</sup> The BPO Products were incubated at 37°C for four weeks and 50°C for three weeks and benzene concentration was measured at certain time intervals using GC-MS. Benzene findings were plotted in real time and reported in ppm. The results below were submitted to the FDA in Valisure's March 5, 2024 Citizen's Petition on Benzoyl Peroxide.<sup>48</sup>



<sup>44</sup> See Valisure Citizen's Petition on Benzoyl Peroxide (March 5, 2024).


<sup>45</sup> *Id.*

<sup>46</sup> Ghimire, Prakash et al., *Guidelines on Stability Studies of Pharmaceutical Products and Shelf-Life Estimation*. INTERNATIONAL JOURNAL OF ADVANCES IN PHARMACY AND BIOTECHNOLOGY, (2020). 06. 15-23. 10.38111/ijapb.20200601004.


<sup>47</sup> Grundstein A, Meentemeyer V, Dowd J. *Maximum vehicle cabin temperatures under different meteorological conditions*. Int J Biometeorol. 2009 May;53(3):255-61. doi: 10.1007/s00484-009-0211-x. Epub 2009 Feb 21. PMID: 19234721.

<sup>48</sup> See Valisure Citizen's Petition on Benzoyl Peroxide (March 5, 2024).


## 4B




## 4C




## 4D




## 4E




## 4F



## 4G



## 4H



46. Valisure found the BPO formulated products were not chemically stable and yielded benzene at levels well over 2 ppm, the maximum amount allowed in any U.S. regulated drug. Some of the benzene levels were many times higher than 2 ppm reaching as high as 1700 ppm for Proactiv's 2.5% BPO Cream and over 400 ppm for Proactiv's 5.0% BPO Cream.<sup>49</sup> The concentration of BPO in the Products did not influence the benzene levels *e.g.*, Target's Up & Up BPO Lotion and Proactiv's 10% BPO Cream yielded similar benzene results in the range of 600 ppm.

47. Unexpectedly, the testing showed that benzene vapors leaked from some of the Products' packaging contaminating the surrounding air even when the packaging was closed raising concern for additional inhalation exposures.<sup>50</sup>

48. Valisure concluded that all on-market BPO acne formulations seem to be fundamentally unstable and form unacceptably high levels of benzene under normal use, handling, and storage temperatures, but no such evidence was observed for acne treatment products not formulated with BPO.<sup>51</sup> The finding that additional benzene leaked into the surrounding air from the Products' containers means the total consumer benzene exposure would be even more dangerous than the levels reported.

49. Valisure filed a Citizen's Petition on Benzoyl Peroxide on March 5, 2024<sup>52</sup> requesting the FDA Commissioner to immediately demand a recall of all Products formulated with BPO and

<sup>49</sup> *Id.*

<sup>50</sup> *Id.*

<sup>51</sup> *Id.*

<sup>52</sup> As of the date of filing this Class Action, Valisure's FDA Petition was pending.

1 further to require that drug manufacturers do independent chemical verification.<sup>53</sup> The Petition is  
 2 pending.

### 3 **VI. DEFENDANT EXPOSED PLAINTIFFS AND THE CLASS TO BENZENE, A KNOWN** 4 **HUMAN CARCINOGEN, WITHOUT THEIR KNOWLEDGE**

5 50. Although benzene has been found in the BPO Products and released into the  
 6 surrounding air from the packaging, Defendant did not list benzene among the Products' ingredients,  
 7 on the Products' label or container, or anywhere in their advertising or on their websites. Defendant  
 8 did not warn that the Products had benzene, are at risk of benzene contamination, or that the Products  
 9 could cause consumers to be exposed to benzene even when sealed.

10 51. Benzene is a carcinogen that has been among the most studied toxins over the last 100  
 11 years due to its wide use during the industrial revolution, extreme danger, and known ability to cause  
 12 cancer and death in humans and animals. The medical literature linking benzene to blood cancers is  
 13 vast dating to the 1930s.<sup>54</sup> Benzene is the foundation component for many chemicals used to make  
 14 plastics, resins, synthetic fibers, paints, dyes, detergents, drugs, and pesticides. Benzene was widely  
 15 used as a solvent in industrial paints, paint removers, adhesives, degreasing agents, denatured alcohol,  
 16 and rubber cements. Benzene use has declined due to the proliferation of worker studies and an ever-  
 17 growing body of evidence confirming benzene's contribution to blood cancers.

18 52. Benzene has no known safe level of exposure.<sup>55</sup> Benzene causes central nervous system  
 19 depression and destroys bone marrow, leading to injury in the hematopoietic system.<sup>56</sup> The  
 20 International Agency for Research on Cancer ("IARC") classifies benzene as a "Group 1 Carcinogen"

21  
 22  
 23 <sup>53</sup> Valisure, LLC, (March 6, 2024), *Valisure Discovers Benzoyl Acne Treatment Products are Unstable and Form Benzene*, <https://www.valisure.com/valisure-newsroom/valisure-detects-benzene-in-benzoyl-peroxide> (last visited March 6, 2024).

24 <sup>54</sup> See Hamilton A., *Benzene (benzol) poisoning*, ARCH PATHOL., (1931):434-54, 601-37; Hunter FT, *Chronic exposure to benzene (benzol). Part 2: The clinical effects*. J. IND. HYG TOXICOL., (1939):21 (8) 331-54; Mallory TB, et al., *Chronic exposure to benzene (benzol).Part 3:The pathological results*. J. IND. HYG TOXICOL.,(1939):21 (8) 355-93; Erf LA, Rhoads CP., *The hematological effects of benzene (benzol) poisoning*. J. IND. HYG TOXICOL., (1939):21 421-35; American Petroleum Institute, *API Toxicological Review: Benzene*, NEW YORK, (1948); Infante PF, Rinsky RA, Wagoner JK, et al., *Leukemia in benzene workers*,LANCET, (1977);2 (8028): 76-78.

27 <sup>55</sup> Harrison R, Saborit, J., *WHO Guidelines for Indoor Air Quality – Selected Pollutants*, (2010); see also Smith, Martyn T. (2010). Advances in Understanding Benzene Health Effects and Susceptibility. *Annual Review of Public Health*, (2010) Vol. 31:133-148.

28 <sup>56</sup> FDA Toxicological Data for Class 1 Solvents, Appendix 4, *Benzene*, <https://www.fda.gov/media/71738/download>.

1 that causes cancer in humans, including acute myelogenous leukemia (“AML”).<sup>57</sup> AML is the  
 2 signature disease for benzene exposure with rates of AML particularly high in studies of workers  
 3 exposed to benzene.<sup>58</sup>

4 53. Benzene exposure is cumulative and additive. There is no safe level of exposure to  
 5 benzene, and all exposures constitute some risk in a linear, if not supralinear, and additive fashion.”<sup>59</sup>

6 54. The Agency for Toxic Substances and Disease Registry’s (“ATSDR”) “Tox Facts” for  
 7 benzene warns that people can be exposed to benzene vapors from benzene-containing products and  
 8 that benzene harms the blood marrow, causing leukemia and anemia, and affects the immune system  
 9 leaving victims vulnerable to infection.<sup>60</sup>

10 55. According to the FDA, benzene in small amounts over long periods of time can  
 11 decrease the formation of blood cells and long-term exposure through inhalation, oral intake, and skin  
 12 absorption may result in cancers such as leukemia and other blood disorders.<sup>61</sup>

13 56. Benzene is a major industrial chemical made from coal and oil that is heavily regulated  
 14 by the EPA as an important environmental pollutant that negatively affects the soil, air, and  
 15 groundwater. Waste and air emissions containing benzene are considered hazardous waste. The coal,  
 16 oil, paint, and chemical industries are heavily regulated due to the emission of carcinogens including  
 17 benzene from refining and other industries processes involving benzene and benzene byproducts,  
 18 which can end up in the air, water, and food supply.

19 57. Benzene is heavily regulated to protect public health and should not be in drug  
 20 products, especially ones such as acne treatment that are used daily by children and teenagers for  
 21 many years. The FDA drug guidelines specify that benzene must not be used to make drugs products  
 22 because of the unacceptable toxicity and deleterious environmental effects.<sup>62</sup> The FDA allows one  
 23

24 <sup>57</sup> International Agency for Research on Cancer. *Benzene, IARC Monographs on the Evaluation of Carcinogenic  
 Risks to Humans, Volume 120*, LYON, France: World Health Organization, (2018).

25 <sup>58</sup> American Cancer Association, *Benzene and Cancer Risk*, [https://www.cancer.org/cancer/risk-  
 prevention/chemicals/benzene.html](https://www.cancer.org/cancer/risk-prevention/chemicals/benzene.html) (last visited October 20, 2023).

26 <sup>59</sup> Smith, Martyn T., *Annual Review of Public Health*, ADVANCES IN UNDERSTANDING BENZENE HEALTH EFFECTS AND  
 SUSCEPTIBILITY (2010) Vol. 31:133-148.

27 <sup>60</sup> Agency for Toxic Substances and Disease Registry, *Benzene – Tox Facts*, CAS # 71-43-2.

28 <sup>61</sup> Federal Drug Administration. (June 9, 2022). *Frequently Asked Questions*: [https://www.fda.gov/drugs/drug-  
 safety-and-availability/frequently-asked-questions-benzene-contamination-drugs](https://www.fda.gov/drugs/drug-safety-and-availability/frequently-asked-questions-benzene-contamination-drugs).

<sup>62</sup> Food and Drug Administration, *Q3C – Tables and Lists Guidance for Industry*,  
<https://www.fda.gov/media/71737/download> (last visited September 26, 2023).



1 limited exception – where the use of benzene in a drug product is unavoidable to produce a drug  
 2 product with a significant therapeutic advance. In that instance, benzene must be restricted to two  
 3 parts per million (ppm).<sup>63</sup> Defendant’s BPO Products do not meet this rare exception.

4 58. Benzene is heavily regulated in the workplace. The U.S. Occupational Safety and  
 5 Health Administration (“OSHA”) set an eight-hour exposure standard of 1 ppm.<sup>64</sup> The National  
 6 Institute for Occupational Safety and Health (“NIOSH”) established a recommended exposure level  
 7 (REL) of 0.1 ppm (15-minute ceiling limit). Subsequent exposure studies known as the “China  
 8 studies” confirmed cancer at levels below 1 ppm.<sup>65</sup> The benzene levels created from Defendant’s  
 9 BPO Products are many times higher than the levels reported in these worker studies and the  
 10 acceptable limits set by regulators.

11 59. Benzene can also pass from the mother’s blood to a developing fetus causing the baby  
 12 to be exposed to benzene.<sup>66</sup> Animal studies have shown low birth weights, delayed bone formation,  
 13 and damage to the bone marrow of developing offspring when pregnant animals breathed benzene.<sup>67</sup>

14 60. Plaintiffs and the Class were exposed to benzene from the BPO Products by inhalation  
 15 and dermal absorption. Benzene can be absorbed into the body via inhalation, skin absorption,  
 16 ingestion, and/or eye contact.<sup>68</sup> Plaintiffs and the Class applied the BPO Products to areas of the skin  
 17 including the face, neck, chest, and back one to three times per day and used the BPO Products as  
 18 washes or scrubs in heated showers. Plaintiffs and the Class were also exposed to benzene leaked  
 19 from contaminated BPO Products.

20 **VII. DEFENDANT MARKETING ITSELF AS EXPERTS BUT CONCEALED FROM**  
 21 **PLAINTIFFS AND THE CLASS THEIR FAILURE TO TEST THE BPO PRODUCTS**  
 22 **FOR SAFETY**

23 61. Defendant told Plaintiffs and the Class BPO is typically safe to use for an extended  
 24

---

25 <sup>63</sup> *Id.*

26 <sup>64</sup> OSHA. Occupational exposure to benzene: Final rule. Fed. Reg. 1987;52-34460-578.

27 <sup>65</sup> See Lan Q, Zhang L et al., *Hematotoxicity in Workers Exposed to Low Levels of Benzene*, SCIENCE, (December 3,  
 28 2004); Costa-Amaral I, V. B. L., *Environmental Assessment and Evaluation of Oxidative Stress and Genotoxicity*  
*Biomarkers Related to Chronic Occupational Exposure to Benzene*, INT J ENVIRON RES PUBLIC HEALTH, (2019) Jun; 16(12):  
 2240.

<sup>66</sup> *Id.*

<sup>67</sup> *Id.*

<sup>68</sup> Centers for Disease Control and Prevention, *The National Institute for Occupational Safety and Health Pocket*  
*Guide to Chemical Hazards, Benzene Exposure Limits*, <https://www.cdc.gov/niosh/npg/npgd0049.html>.



period of time.”<sup>69</sup> Defendant’s mislead the Plaintiffs and the Class because Defendant’s BPO Products degrade to benzene, during normal and expected handling, use, or storage, exposing consumers to benzene, and an increased risk of cancer.

62. Defendant told Plaintiffs and the Class it is a leader in the industry, committed to continuous innovation, and “science-based solutions.”<sup>70</sup> Defendant promised it only used “eco-certified ingredients” and “FDA compliant ingredients” for over-the-counter use.<sup>71</sup> Defendant said BPO and salicylic acid have advantages for acne treatment and complement each other.<sup>72</sup> Defendant did not say that BPO degrades to benzene, and salicylic acid did not.

63. Defendant’s misrepresentations about its BPO Products and omissions of material health and safety information were misleading and deceptive. Defendant’s BPO Products had the highest levels of benzene when tested in 2023 by Valisure, *i.e.*, Proactive 2.5% BPO Cream was close to 1700 ppm, many multiple times higher than legal limits.

64. Defendant’s broad claims of safety in their marketing, social media, and on websites gave Plaintiffs and the Class a false sense of safety leading them to believe the BPO Products were safe. Defendant made these statements uniformly to Plaintiffs and the Class while shirking its responsibility to do adequate and meaningful testing before selling the Products to the public.

#### **VIII. DEFENDANT DID NOT WARN PLAINTIFFS AND THE CLASS THE BPO PRODUCTS WERE AT RISK OF BENZENE CONTAMINATION**

65. Defendant represented to the Plaintiffs, the Class, and the public that each of their Products had only the ingredients listed on the label and package in advertising and on websites, but none identified benzene anywhere.

66. Defendant told Plaintiffs and the Class BPO is a “tried and true” ingredient that has been the “gold standard for acne treatment for 50 years.”<sup>73</sup> BPO was safe to use “for an extended

<sup>69</sup> See Proactive.com, Acne Treatment Ingredients [Tab], retrieved from: <https://www.proactiv.com/blog/acne-skin-care-ingredients> (last visited March 7, 2024).

<sup>70</sup> Alchemee, *Innovation*, <https://www.alchemee.com/innovation> (last visited November 6, 2023).

<sup>71</sup> *Id.*

<sup>72</sup> Alchemee LLC, *Is Salicylic Acid or Benzoyl Peroxide Better?* <https://www.proactiv.com/blog/acne-skin-care-ingredients/salicylic-acid> (visited October 25, 2023).

<sup>73</sup> Alchemee LLC, *What Is Benzoyl Peroxide?* [s://www.Proactiv.Com/Blog/Acne-Skin-Care-Ingredients/Benzoyl-Peroxide](https://www.Proactiv.Com/Blog/Acne-Skin-Care-Ingredients/Benzoyl-Peroxide) (last visited October 25, 2023).

period of time.”<sup>74</sup> None of the Proactiv BPO Products listed benzene on the label, container, or anywhere on Defendant’s website or advertising.<sup>75</sup> Defendant assured Plaintiffs and the Class that any side effects from Proactiv were “usually mild such as drying and irritation.”<sup>76</sup>

104. Defendant’s statements about the BPO Products’ ingredients were false, deceptive, and misleading. Defendant’s statements were meant to convey to Plaintiffs, the Class, and the public the Products were safe and did not have carcinogens such as benzene. Defendant made these statements to the Plaintiffs and the Class, and omitted benzene from all advertising, labeling, and packaging when Defendant knew or should have known the statements were false, misleading, and deceptive. Reasonable consumers, relying on Defendant’s statements reasonably believed the BPO Products were safe and did not have benzene.

## **IX. DEFENDANT AGGRESSIVELY DIRECTLY MARKETING TO CHILDREN AND TEENAGERS**

67. Defendant’s BPO Products are widely used by children and teenagers as a standalone treatment or combined with other BPO Products. Defendant knew that adolescents are the largest users with users as young as 7-10 years old. Defendant recommended that consumers, including children, use the BPO Products one to three times a day, over many months or longer for persistent acne. Defendant knew that some consumers would use the BPO Products for many years starting in their teens. There is no cure for acne. Defendant knew that consumers with chronic acne would use their BPO Products several times a day throughout their lifetime.

68. Defendant aggressively marketed the BPO Products directly to children and teenagers knowing, or they should have known, the BPO Products degrade to benzene under normal use and storage conditions. Many of Defendant’s online and print advertisements featured children, teenagers, eye-catching props, music, and colors meant to attract teens and pre-teens, and appeal to their preferences, activities, and interests.

69. Defendant encouraged parents to start treating teenage acne early with benzoyl peroxide

---

<sup>74</sup> *Id.*

<sup>75</sup> *See e.g.*, Proactiv Repairing Treatment Package, 2 Fl Oz [60 ml].

<sup>76</sup> Alchemee LLC, *Does Proactiv Have Any Side Effects?* <https://www.Proactiv.Com/Faqs>, (last visited October 25, 2023).

1 drug products.<sup>77</sup> Defendant promised the Products were “safe and effective for teens” and “penetrate  
2 deeply into the pores to kill acne.”<sup>78</sup>

3 70. Defendant’s marketing of BPO Products without mentioning benzene, the risk of  
4 benzene exposure, or testing for benzene waste and continues to be misleading, fraudulent, deceptive,  
5 and dangerous.

### 6 **PUNITIVE DAMAGES ALLEGATIONS**

7 71. Defendant’s conduct was done with malice and reckless disregard for human life.  
8 Defendant knew the BPO Products degraded to benzene when exposed to heat under normal  
9 consumer use, handling, and storage conditions. Defendant further knew that benzene is a known  
10 human carcinogen that is not supposed to be in the BPO Products due to the grave risk of harm to  
11 consumers. Defendant disregarded this information and the known risks of benzene exposure and  
12 deliberately omitted benzene from the list of ingredients, the BPO Products’ labels, and their social  
13 media and websites where information about the BPO Products is found. Defendant consciously and  
14 deliberately crafted the BPO Products’ marketing, labels, packaging, containers, and warnings  
15 intending to mislead Plaintiffs, the Class, and the public, and lead them to believe the BPO Products  
16 were safe and carcinogen-free.

17 72. Defendant marketed itself as expert drug formulators, researchers, and merchandisers  
18 skilled in developing safe and reliable products while withholding material health and safety  
19 information Defendant knew was essential to informed consumer decision making. Defendant knew  
20 that, by their conduct, they were robbing Plaintiffs, the Class, and the public of their right to choose  
21 safe products.

22 73. Defendant was on notice of benzene findings in consumer and drug products leading to  
23 widely publicized recalls. Defendant was on notice of the FDA’s concerns of benzene contamination  
24 in drug and consumer products and received the FDA’s 2022 directive to test Products for benzene  
25 contamination. Defendant disregarded these notices and continued to market and sell the BPO  
26 Products without testing them for benzene.

27  
28 <sup>77</sup> Proactiv, *Proactiv Blog, 5 Reasons to Treat Acne Early*, <https://www.proactiv.com/blog/treating-face-acne/reasons-to-treat-bad-teenage-acne-early> (last visited October 7, 2023).

<sup>78</sup> *Id.*

74. Defendant knew their decisions and chosen course of conduct was risky and would cause consumers such as the Plaintiffs and the Class to be exposed to benzene. Defendant's conduct was not by accident, but was deliberate, calculated, and informed. Defendant knew they could sell more BPO Products and earn more money by concealing material human health and safety information. Defendant further knew that testing the BPO Products for benzene would yield findings of benzene requiring recalls and/or a shutdown of production causing significant losses of income. Defendant's goals were met not only because of their false and deceptive advertising, labeling, and packaging, but through a comprehensive scheme of aggressive marketing and image branding leading consumers to believe they were acne treatment experts dedicated to drug research, development, and safety and using only the safest ingredients and formulations that would remain pure and stable until the designated end. Defendant's conduct and concealment of material health information was done to further their own monetary gain and with conscious disregard of the Plaintiffs, the Class, and the public's right to choose safe products. Defendant's conduct was intentional, calculated, blatantly deceptive, unscrupulous, and offensive to consumer health and public policy. To redress the harms caused by Defendant's conduct, Plaintiffs, on behalf of themselves and the Class, seek punitive damages against the Defendant.

#### **PLAINTIFF SPECIFIC ALLEGATIONS**

75. Plaintiff Efren Ramos is a California resident who places a high priority on health and safety, and on the adverse health consequences of exposure to carcinogens such as benzene. In shopping for drug products for his skin and face, Plaintiff Efren Ramos was particularly concerned about the product being cost effective and having fast results. Plaintiff recalls seeing Proactiv infomercials as a teenager, and as Proactiv became available in stores and online, he was more inclined to buy the Products without the subscription. Based on the statements made by Defendant, their widely recognized name, and lack of information that the Products had carcinogens such as benzene, Plaintiff believed the Products were safe to put on his skin. Defendant's representations and omissions of human health and safety information were material to Plaintiff.

76. Plaintiff Ramos bought Proactiv Renewing Cleanser and used it from 2017 to February 2024 for his oily skin and breakouts. Plaintiff was unaware when he bought the Product that it was

1 contaminated with benzene or degraded to benzene. Had Defendant been truthful and told Plaintiff he  
2 would be exposed to benzene and/or be at increased risk of cancer, he would not have bought Proactiv  
3 Renewing Cleanser.

4 77. Plaintiff Ramos suffered an ascertainable economic loss because of Defendant's  
5 statements and misrepresentations because he bought the Product he would not have bought but for  
6 Defendant's statements and misrepresentations.

7 78. Plaintiff Joshua Cross is a California resident who places a high priority on health and  
8 safety, and on the adverse health consequences of exposure to carcinogens such as benzene. In  
9 shopping for drug products for his skin and face, Plaintiff Joshua Cross was particularly concerned  
10 about the product being safe and effective. Plaintiff recalls seeing advertisements on television by  
11 Defendant before buying them in the store. Based on the statements made by Defendant, their widely  
12 recognized name, and lack of information that the Products had carcinogens such as benzene, Plaintiff  
13 believed the Products were safe to put on his skin. Defendant's representations and omissions of  
14 human health and safety information were material to Plaintiff.

15 79. Plaintiff Cross bought Proactiv+ Skin Smoothing Exfoliator, Proactiv Solution  
16 Renewing Cleanser, Proactiv+ Pore Targeting Treatment, and Proactiv Emergency Blemish Relief and  
17 used it from January 2022 to December 2023. Plaintiff was unaware when he bought the Products that  
18 it was contaminated with benzene or that it could degrade to benzene. Had Defendant been truthful  
19 and told Plaintiff he would be exposed to benzene and/or be at increased risk of cancer, he would not  
20 have bought Proactiv+ Skin Smoothing Exfoliator, Proactiv Solution Renewing Cleanser, Proactiv+  
21 Pore Targeting Treatment, and Proactiv Emergency Blemish Relief.

22 80. Plaintiff Cross suffered an ascertainable economic loss because of Defendant's  
23 statements and misrepresentations because he bought the Product he would not have bought but for  
24 Defendant's statements and misrepresentations.

25 81. Plaintiff Marisol Scharon is a California resident who places a high priority on health  
26 and safety, and on the adverse health consequences of exposure to carcinogens such as benzene. In  
27 shopping for drug products for her skin and face, Plaintiff Marisol Scharon was particularly concerned  
28 about the safety and effectiveness to control the acne on her face. Plaintiff read the front labeling of

1 the product which encouraged her to buy the product by Defendant. Based on the statements made by  
2 Defendant, their widely recognized name, and lack of information that the Products had carcinogens  
3 such as benzene, Plaintiff believed the Products were safe to put on her skin. Defendant's  
4 representations and omissions of human health and safety information were material to Plaintiff.

5 82. Plaintiff Sharon bought Proactiv Solution Repairing Treatment, Proactiv Renewing  
6 Cleanser, Proactiv+ Pore Targeting Treatment and Proactiv Emergency Blemish Relief and used it  
7 from August 2016 to March 2021 for the acne on her face. Plaintiff was unaware when she bought the  
8 Products that it was contaminated with benzene or that it could degrade to benzene. Had Defendant  
9 been truthful and told Plaintiff she would be exposed to benzene and/or be at increased risk of cancer,  
10 she would not have bought Proactiv Solution Repairing Treatment, Proactiv Renewing Cleanser,  
11 Proactiv+ Pore Targeting Treatment and Proactiv Emergency Blemish Relief.

12 83. Plaintiff Sharon suffered an ascertainable economic loss because of Defendant's  
13 statements and misrepresentations because she bought the Product she would not have bought but for  
14 Defendant's statements and misrepresentations.

### 15 **CLASS ACTION ALLEGATIONS**

16 84. Plaintiffs bring this case on behalf of themselves, and all others similarly situated as a  
17 Class Action under CAL. CIV. CODE § 382. Plaintiffs seek to represent a California Class of consumers  
18 who bought Defendant's Products for use and not for resale. Excluded from this Class is Defendant,  
19 its employees, co-conspirators, officers, directors, legal representatives, heirs, successors, and  
20 affiliated companies; Class counsel and their employees; and judicial officers and their immediate  
21 families as court staff assigned to the case.

22 85. The Class does not seek damages for physical injuries, although each Plaintiff was  
23 physically harmed by being exposed to benzene.

24 86. This action has been brought and may be properly maintained as a Class Action under  
25 CAL. CIV. CODE § 382 because there is a well-defined community of interest and the proposed Class  
26 meets the class action requirements of numerosity, commonality, typicality, and adequacy of  
27 representation.

28 87. Defendant engaged in a common course of conduct giving rise to the legal rights sought

1 to be enforced by Plaintiffs, on behalf of themselves, and the other Class members. Similar or  
 2 identical statutory and common law violations, business practices, and injuries are involved.

3 88. **Numerosity.** Plaintiffs believe there are thousands of Class members making the Class  
 4 so numerous and geographically dispersed that joining all members is inconvenient and impracticable.

5 89. **Commonality.** There are questions of law and fact common to all Class members that  
 6 predominate over questions which affect only individual Class members. All Class members were  
 7 deceived and misled by Defendant through the same advertising, online representations, labeling, and  
 8 packaging, which do not mention benzene and misrepresent the characteristics, ingredients, and safety  
 9 of the BPO Products. All Class members bought Defendant's BPO Products and have suffered an  
 10 economic loss because of Defendant's deceptions and omissions. Thus, there is a well-defined  
 11 community of interest in the questions of law and facts common to all Class members. Other  
 12 common questions of law and fact in this dispute include, without limitation:

- 13 a. Whether Defendant's Products degrade to benzene under normal handling, use, and  
 14 storage conditions.
- 15 b. Whether Defendant's tested the Products for benzene before selling them.
- 16 c. When Defendant knew or should have known the Products degraded to benzene.
- 17 d. Whether Defendant's advertising omitting benzene was deceptive, fraudulent, or unfair.
- 18 e. Whether Defendant's advertising omitting benzene was likely to deceive reasonable  
 19 consumers.
- 20 f. Whether Defendant's conduct violated California's Unfair Competition Law, Bus. &  
 21 Prof. Code § 17200 *et seq.*
- 22 g. Whether Defendant's conduct violated California's False Advertising Law, Bus. & Prof.  
 23 Code § 17500 *et seq.*
- 24 h. Whether Defendant's conduct violated California's Consumer Legal Remedies Act.
- 25 i. Whether Defendant breached the express and implied warranties it made about the  
 26 Products.
- 27 j. Whether Defendant was unjustly enriched by its misconduct.
- 28 k. Whether the Plaintiffs and the proposed Class have been injured and if so, what is the



proper measure of damages.

1. Whether the Plaintiffs and the proposed Class have the right to economic damages including compensatory, exemplary, and statutory remedies for Defendant' misconduct.
- m. Whether the Plaintiffs and the proposed Class have the right to injunctive, declaratory, or other equitable relief and attorneys' fees.

90. **Typicality.** The Plaintiffs' claims are typical of the claims of the Class because the claims arise from the same course of misconduct by Defendant, *i.e.*, Defendant's false and misleading advertising and their failure to disclosure benzene in the Products. The Plaintiffs, and all Class members were exposed to the same uniform and consistent advertising, labeling, and packaging statements Defendant made about the Products. Because of the Defendant' misconduct, Plaintiffs, like all Class members, were damaged and have incurred economic loss because of buying the Products believed to be safe. The claims of the Plaintiffs are typical of Class.

91. **Adequacy.** The Plaintiffs will fairly and adequately represent and protect the interests of all Class members. Plaintiffs have no interests antagonistic to the Class members. Plaintiffs hired attorneys experienced in the prosecution of consumer Class Actions and Plaintiffs intend to prosecute this action vigorously. Plaintiffs expect no difficulty in the management of this litigation as a Class Action.

92. Finally, this Class Action is proper under CAL. CIV. CODE § 382 because, under these facts, a Class Action is superior to other methods and is the most efficient method for the fair and efficient adjudication of the dispute. The Class members have all suffered economic damages because of Defendant's deceptive trade practices, false advertising, and omissions of material health and safety information. Because of the nature of the individual Class members' claims and the cost of the Products, few, if any individuals, would seek legal redress against Defendant because the costs of litigation would far exceed any potential economic recovery. Without a Class Action, individuals will continue to suffer economic losses for which they would have no remedy, and Defendant will unjustly continue their misconduct with no accountability while keeping the profits of their ill-gotten gains. Even if separate cases could be brought by individuals, the resulting multiplicity of lawsuits would cause undue hardship, burden, and expense for the Court and the litigants, as well as create a risk of



inconsistent rulings across the country, which might be dispositive of the interests of individuals who are not parties. A Class Action furthers the important public interest of containing legal expenses, efficiently resolving many claims with common facts in a single forum simultaneously, and without unnecessary duplication of effort and drain on critical judicial resources. The Class Action method presents far fewer management difficulties than individual cases filed state wide and provides the benefit of comprehensive supervision by a single court.

### **CAUSES OF ACTION**

#### **I. VIOLATION OF CALIFORNIA’S UNFAIR COMPETITION LAW BUS. & PROF. CODE § 17200 *et seq.***

93. Plaintiffs reallege and incorporate all other paragraphs in this Class Action Complaint and further allege:

94. Plaintiffs bring this cause of action on behalf of themselves, and all members of the California Class, all of whom are similarly situated consumers.

95. California’s Unfair Competition Law, CAL. BUS. & PROF. CODE § 17200, *et seq.*, prohibits “unlawful, unfair, or fraudulent business act or practices” and “unfair, deceptive, untrue or misleading advertising.” Defendant misrepresented their Products in advertising, labels, and containers and misled Plaintiffs and the Class about the ingredients, characteristics, purity, quality, approval, and safety of the Products. Defendant led Plaintiffs and the Class to believe the Products were safe.

96. Defendant’s advertising, online representations, labeling, and packaging of the Products were misleading, fraudulent, and deceptive. Defendant knew through the Products’ development, formulation, research, and pre-sale safety and stability testing, the Products were not chemically and physically stable when exposed to common temperatures. Defendant knew or should have known the Products formulated benzene under normal and expected consumer use, handling, and storage conditions, and that consumers would be exposed to benzene. Defendant was specifically reminded by the FDA of their obligation to ensure the safety and quality of their Products, including testing them for benzene before selling them to the public, but shirked their duties and continued to market and sell the Products without substantiating their safety, or warning Plaintiffs and the Class about benzene.

1           97. Defendant omitted material health and safety information, *e.g.*, benzene, from the  
2 Products' advertising, label, container, and warnings. Defendant did not tell Plaintiffs and the Class  
3 members they would be exposed to benzene, a human carcinogen, during normal and expected  
4 handling, use and storage of the Products, even with the Products' container closed.

5           98. Defendant's acts and omissions were likely to deceive reasonable consumers and the  
6 public. Reasonable consumers expect to be told about all ingredients in Products. Reasonable  
7 consumers further expect that carcinogens in the Products be disclosed. Reasonable consumers further  
8 expect that on market drugs to be free of carcinogens, unless told otherwise. Benzene is a widely  
9 marketed drug product used by children, teens, and the public is material health information  
10 reasonable consumers expect to be told.

11           99. Had Defendant been truthful in their advertising, labeling, packaging, and online  
12 statements about benzene in the Products, or the risk of contamination, and the risk of cancer,  
13 Plaintiffs and the Class members would not have bought the Products.

14           100. Defendant's acts, omissions, and concealment of material health and safety information  
15 are ongoing and continuing to cause harm. Defendant continues to market, advertise, and sell the  
16 Products to the public without telling the public about benzene in the Products, or the risk of  
17 contamination, and the risk of cancer. Defendant continues to market themselves as responsible drug  
18 manufacturers and sellers who sell safe products when they have not tested the Products for benzene  
19 or measured the levels of benzene formed in the Products during normal and expected storage  
20 conditions.

21           101. Defendant engaged in these deceptive practices for significant financial gain, which is  
22 unfair, unreasonably dangerous to Plaintiffs and the Class members, and not outweighed by any  
23 benefit to Plaintiffs, the Class members, or the public. Omitting and concealing material human  
24 health and safety information such as benzene in the Product and the consumers' risk of cancer from  
25 the Products is unethical, unscrupulous, and offensive.

26           102. Plaintiffs suffered ascertainable economic losses because of Defendant's misconduct  
27 because they bought the Products they otherwise would not have bought but for Defendant's  
28 misrepresentations and affirmations of safety.

103. Because of Defendant's misconduct, Plaintiffs, on behalf of themselves and the Class, seek recovery of their economic damages, attorneys' fees, restitution, and all other relief allowable under CAL. BUS. & PROF. CODE § 17200, *et seq.*, including an injunction to enjoin Defendant from continuing their fraudulent and deceptive business practices. The damages sought are ascertainable, uniform to the Class and can be measured and returned to the Class members.

**II. VIOLATION OF CALIFORNIA'S CONSUMER LEGAL REMEDIES ACT, CAL. CIV. CODE § 1750, *et seq.*,**

104. Plaintiffs reallege and incorporate all other paragraphs in this Complaint and further allege:

105. Plaintiffs bring this cause of action on behalf of themselves, and all members of the California Class, all of whom are similarly situated consumers within the meaning of CAL. CIV. CODE § 1781.

106. Defendant's acts and omissions violated California's Consumer Legal Remedies Act, CAL. CIV. CODE § 1750, *et seq.*, enacted to protect consumers from being victimized and deceived by advertisers, distributors, and sellers like the Defendant.

107. California's Consumer Legal Remedies Act, CAL. CIV. CODE § 1750, *et seq.* prohibits unfair methods of competition and unfair or deceptive acts or practices in connection with the sale of consumer goods. Defendant violated several prohibitions of CIV. CODE § 1750(a).

108. Defendant violated CAL. CIV. CODE § 1750(a)(2) by representing the source, sponsorship, and approval, of the Products, *e.g.*, the Products were backed by sound scientific principles, that Defendant met its obligations to conduct adequate and meaningful quality and safety testing before selling the Products to the public, and represented the Products only had the ingredients listed, and were free of carcinogens.

109. Defendant violated CAL. CIV. CODE § 1750(a)(3) by representing the affiliation, connection, or association with, or certification by, another *e.g.*, the Products were approved by dermatologists and made in conformity with current good manufacturing practices.

110. Defendant violated CAL. CIV. CODE § 1750 (a)(4) by using deceptive representations, *e.g.*, the Products were safe, validated, and supported by the latest research, and free of carcinogens

1 such as benzene.

2 111. Defendant violated CAL. CIV. CODE § 1750(a)(5) by representing the Products have  
3 characteristics, ingredients, uses, or benefits, which they do not, *e.g.*, misleading Plaintiffs and the  
4 Class members the Products only had the listed ingredients, did not have benzene, and did not  
5 increase the risk of the consumers' risk of cancer.

6 112. Defendant violated CAL. CIV. CODE § 1750(a)(6) by representing the Products were not  
7 deteriorated unreasonably or altered *e.g.*, the Products were pure and had not degraded or formed  
8 benzene.

9 113. Defendant violated CAL. CIV. CODE § 1750(a)(7) by representing the Products were  
10 pure and of a particular standard or quality, when they are not, and the Products were safe,  
11 dermatologist approved, and not carcinogenic.

12 114. Defendant violated CAL. CIV. CODE § 1750(a)(9) by advertising the Products with the  
13 intent not to sell them as advertised, *e.g.*, the Products were of pure quality, safe, made in conformity  
14 with current good manufacturing practices, and not adulterated.

15 115. Had Defendant been truthful in their advertising, labeling, packaging, warnings, and  
16 online statements about benzene in the Products and the risk of cancer, Plaintiffs and the Class  
17 members would not have bought the Products. Benzene, a human carcinogen, in a widely marketed  
18 and available consumer drug product, is material health and safety information Defendant knew  
19 Plaintiffs, the Class members, and the public would want to know. The Defendant's omission of this  
20 material information was common to all Class members and made to all Class members uniformly  
21 through common advertising, online representations, labeling, and packaging.

22 116. Defendant's acts, omissions, and concealment of material health and safety information  
23 are ongoing and continuing to cause harm. Defendant continues to market, advertise, and sell the  
24 Products to the public without telling the public about benzene in the Products and the risk of cancer.  
25 Defendant continues to market themselves as responsible drug manufacturers and sellers who sell safe  
26 products when they have not measured the levels of benzene in and created in the Products during  
27 normal and expected storage conditions.

28 117. Defendant engaged in these deceptive practices for significant financial gain, which is

1 unfair, unreasonably dangerous to Plaintiffs and the Class members, and not outweighed by any  
 2 benefit to Plaintiffs, the Class members, or the public. Omitting and concealing material human  
 3 health and safety information such as the consumers' risk of cancer from exposure to the Products is  
 4 unethical, unscrupulous, and offensive.

5 118. Plaintiffs suffered ascertainable economic losses because of Defendant's misconduct  
 6 because they bought the Products, they otherwise would not have but for Defendant's  
 7 misrepresentations.

8 119. Because of Defendant's misconduct, Plaintiffs, on behalf of themselves and the Class  
 9 members, seek recovery of their economic damages, attorneys' fees, punitive damages, restitution,  
 10 and all other relief allowable under CAL. CIV. CODE § 1750, *et seq.*, including an injunction to enjoin  
 11 Defendant from continuing their fraudulent business practices. The damages sought are ascertainable,  
 12 uniform to the Class and can be measured and returned to the Class members.

### 13 **III. VIOLATION OF CALIFORNIA'S FALSE ADVERTISING LAW**

14 120. Plaintiffs reallege and incorporate all other paragraphs in this Complaint and further  
 15 allege:

16 121. Plaintiffs bring this cause of action on behalf of themselves, and all members of the  
 17 California Class, all of whom are similarly situated consumers.

18 122. Defendant developed, researched, manufactured, tested, marketed, and sold the  
 19 Products throughout the United States. Defendant knew through the Products' development,  
 20 formulation, and testing, the Products were not chemically stable when exposed to certain expected  
 21 and normal environmental and storage conditions and can form benzene, as a toxic byproduct. Despite  
 22 this knowledge, Defendant did not mention benzene in the Products' advertising, ingredient list, label,  
 23 container, or warnings. Defendant did not tell Plaintiffs and the Class members they would be exposed  
 24 to benzene, a human carcinogen, during normal and expected handling, use and storage of the  
 25 Products, even with the Products' containers closed.

26 123. Benzene, a human carcinogen, is a widely marketed and available consumer drug  
 27 product, is material health and safety information Defendant knew Plaintiffs, the Class members, and  
 28 the public would want to know. Defendant not only omitted this material human health and safety

1 information from advertising, online representations, blogs, labeling, packaging, and warnings, but  
2 Defendant aggressively marketed themselves as drug experts, innovators, researchers, market leaders,  
3 and companies committed to consumer safety who devote substantial resources to drug research and  
4 development. Defendant's affirmations of safety and responsibility misled Plaintiffs, and the Class  
5 members, leading them to believe the Products were tested, verified, and safe. Defendant further  
6 marketed the Products touting the approval of dermatologists, who were not aware of the presence of  
7 benzene in the Products and of Defendant's refusal to conduct adequate and meaningful testing before  
8 marketing and selling the Products to the public and following the FDA's 2022 alert to specifically  
9 look for benzene.

10 124. Defendant's acts and omissions constitute false advertising. Defendant advertised the  
11 Products with the intent not to sell them as advertised. Reasonable consumers, including Plaintiffs  
12 and the Class members, exposed to Defendant's advertising would believe the Products were safe,  
13 verified, and free of benzene.

14 125. Defendant's false and misleading advertising violated California's False Advertising  
15 Law, Bus. & Prof. Code § 17500 *et seq.*, which prohibits Defendant from disseminating statements  
16 "which are untrue or misleading, and which are known, or which by the exercise of reasonable care  
17 should be known, to be untrue or misleading." Defendant knew or should have known the Products  
18 formed benzene under normal, handling, use, and storage conditions but did not disclose this to  
19 Plaintiffs and the Class members. Defendant knew through the Products' development, formulation,  
20 research, and testing, the Products were not chemically stable when exposed to certain normal and  
21 expected environmental conditions. Defendant knew Plaintiffs, the Class members, and consumers  
22 would be exposed to benzene in the Products, even with the Products' original packaging closed.

23 126. Had Defendant been truthful in their advertising, online representations, labeling, and  
24 packaging about benzene, Plaintiffs and the Class members would not have bought the Products.

25 127. Plaintiffs suffered ascertainable economic losses because of Defendant's misconduct  
26 because they bought the Products, they otherwise would not have but for Defendant's material  
27 misrepresentations.

28 128. Because of Defendant's misconduct, Plaintiffs, on behalf of themselves and the

1 California Class, seek recovery of their economic damages, attorneys' fees, punitive damages,  
2 restitution, and all other relief allowable by law, including an injunction to enjoin Defendant from  
3 continuing their fraudulent business practices. The damages sought are ascertainable, uniform to the  
4 Class and can be measured and returned to the Class members.

5 **IV. BREACH OF EXPRESS WARRANTY**

6 129. Plaintiffs reallege and incorporate all other paragraphs in this Complaint and further  
7 allege:

8 130. Plaintiffs bring this cause of action on behalf of themselves, and all members of the  
9 California Class, all of whom are similarly situated consumers.

10 131. The Uniform Commercial Code § 2-313 provides that an affirmation of fact or promise  
11 made by the seller to the buyer which relates to the goods and becomes part of the basis of the bargain  
12 creates an express warranty that the goods shall conform to the promise. Defendant advertised and  
13 sold the Products as safe, pure, of good quality, and only containing the listed ingredients.  
14 Defendant's advertising, labels, containers, packaging, advertising, and online statements did not  
15 mention benzene, leading consumers to believe the Products were safe for their ordinary use.  
16 Defendant's affirmations were uniformly made to Plaintiffs and the Class members by Defendant in  
17 the Products' advertising, labeling, packaging, and online statements and were part of the basis of the  
18 bargain between Defendant, and the Plaintiffs and Class members.

19 132. Defendant's affirmations and promises are unlawful. When Defendant marketed,  
20 distributed, and sold the Products, Defendant knew, or should have known, the Products degraded to  
21 benzene under normal and expected use, handling, and storage conditions. Defendant knew, or should  
22 have known, the Products formed benzene and therefore did not conform to Defendant's express  
23 representations and warranties to consumers. Plaintiffs and the Class members bought the Products in  
24 reasonable reliance on Defendant's statements.

25 133. Because of Defendant's misconduct, Plaintiffs, on behalf of themselves and the  
26 California Class, seek recovery of their economic damages, attorneys' fees, punitive damages,  
27 restitution, and all other relief allowable by law, including an injunction to enjoin Defendant from  
28 continuing their fraudulent business practices. The damages sought are ascertainable, uniform to the



1 Class and can be measured and returned to the Class members.

2 **V. BREACH OF IMPLIED WARRANTY**

3 134. Plaintiffs reallege and incorporate all other paragraphs in this Complaint and further  
4 allege:

5 135. Plaintiffs bring this cause of action on behalf of themselves, and all members of the  
6 California Class, all of whom are similarly situated consumers.

7 136. Defendant, as sellers of the Products, also made implied warranties including  
8 warranting the Products were of the same quality and purity represented on the labels, in advertising,  
9 and on Defendant's websites, were fit for the ordinary purpose of the Products and conformed to the  
10 promises made on the containers, labels, advertising, and websites that all ingredients were listed, and  
11 all warnings given.

12 137. Defendant advertised their Products as safe, when they knew, or should have known,  
13 the Products degraded to benzene. Defendant did not list benzene as an ingredient or contaminant  
14 anywhere on the Products or advertising. The Products are not of the quality and purity represented  
15 by Defendant because the Products degrade to benzene under normal use, handling, and storage  
16 conditions.

17 138. Defendant did not tell Plaintiffs and the Class members the Products were not fit for  
18 their ordinary use because the Products, as advertised and sold by Defendant, degraded to benzene  
19 under normal and expected handling, use, and storage.

20 139. Defendant's affirmations that the Products were safe for use were uniformly made to  
21 the Plaintiffs and the Class members in the Products' advertising, labeling, and packaging, and on  
22 Defendant's websites and social media sites, which were part of the basis of the bargain.

23 140. Plaintiffs and the Class members bought the Products in reasonable reliance on  
24 Defendant's statements, affirmations, and omissions of material health and safety information.

25 141. Defendant's acts and omissions are ongoing and continuing to cause harm.

26 142. Because of Defendant's misconduct, Plaintiffs, on behalf of themselves, and the  
27 California Class members, seek recovery of their actual damages, injunctive relief, attorneys' fees,  
28 punitive damages, and all other relief allowable under the law. The damages sought are uniform to



the Class and the actual damages can be measured and returned to the Class members who bought Defendant's Products.

## **VI. UNJUST ENRICHMENT**

143. Plaintiffs reallege and incorporate all other paragraphs in this Complaint and further allege:

144. Plaintiffs bring this cause of action on behalf of themselves, and all members of the California Class, all of whom are similarly situated consumers.

145. Defendant has unjustly profited from their deceptive business practices and kept the profits from Plaintiffs and the Class members who bought the Products.

146. Defendant requested and received a measurable economic benefit at the expense of Plaintiffs and the Class members as payment for the Products. Defendant accepted the economic benefits from Plaintiffs and the Class members knowing the economic benefit received was based on deception and omission of material human health and safety information.

147. There is no utility in Defendant's misconduct and Defendant's enrichment from the misconduct is unjust, inequitable, unconscionable, and against the strong public policy to protect consumers against fraud.

148. Because of Defendant's misconduct, Plaintiffs, on behalf of themselves, and the California Class, seek recovery of their actual damages, disgorgement of profits, injunctive relief, attorneys' fees, punitive damages, and all other relief allowable under the law. The damages sought are uniform to the Class and the actual damages can be measured and returned to Class members who bought Defendant's Products.

## **PRAYER FOR RELIEF**

149. WHEREFORE, Plaintiffs pray for judgment against Defendant:

- a. That the Court determine this action may be maintained as a Class Action under CAL. CIV. CODE § 382;
- b. That Defendant's misconduct be adjudged to have violated the California consumer protection laws identified;
- c. That Defendant's misconduct be adjudged to have violated its express and

1 implied warranties to Plaintiffs and the Class;


- 2 d. That injunctive and declaratory relief be awarded against Defendant, including  
3 but not limited to an order prohibiting Defendant from engaging in the alleged  
4 misconduct;
- 5 e. That Defendant be ordered to disgorge profits and revenues derived from their  
6 course of misconduct and that such unjust enrichment be restored to the class  
7 and or distributed cy pres as the Court shall consider just and equitable;
- 8 f. That Plaintiffs recover all compensatory damages and other damages sustained  
9 by Plaintiffs;
- 10 g. That Plaintiffs recover punitive damages as allowed by law;
- 11 h. That Plaintiffs recover all statutory damages as allowed by law;
- 12 i. That Plaintiffs recover their attorneys' fees and all costs of suit;
- 13 j. That Plaintiffs recover all statutory pre-judgment and post-judgment interest on  
14 any amounts; and
- 15 k. That all further relief as this Court may deem just and proper be granted.

16 **DEMAND FOR JURY TRIAL**

17 150. Demand is made for a jury trial.

18  
19 Dated: March 7, 2024

Respectfully Submitted,  
**WISNER BAUM, LLP**

20  
21 

22 Stephanie Sherman, Esq.

[ssherman@wisnerbaum.com](mailto:ssherman@wisnerbaum.com)

23 R. Brent Wisner, Esq.

[rbwisner@wisnerbaum.com](mailto:rbwisner@wisnerbaum.com)

24 11111 Santa Monica Boulevard, Suite 1750

Los Angeles, CA 90025

25 Telephone: (310) 207-3233

26 Facsimile: (310) 820-7444

27 *Counsel for Plaintiffs*